Literature DB >> 11427316

No pathogenic mutations in the synphilin-1 gene in Parkinson's disease.

R Bandopadhyay1, R de Silva, N Khan, E Graham, J Vaughan, S Engelender, C Ross, H Morris, C Morris, N W Wood, S Daniel, A Lees.   

Abstract

alpha-Synuclein is mutated in rare autosomal dominant forms of Parkinson's disease and is a major component of Lewy bodies and neurites. Synphilin-1, a novel protein interacts in vivo and co-localises with alpha-synuclein in Lewy bodies. We analysed the synphilin-1 gene in familial Parkinson's disease by single-strand conformation polymorphism (SSCP) and automated sequencing but found no coding mutations. However, we identified two novel intronic polymorphisms; an A/T polymorphism in intron 2, resulting in the introduction of an Alu1 site and a second G/T polymorphism in intron 4. We analysed the intron 2 polymorphism for allelic association as it was conducive to rapid screening but observed no changes in frequency between Parkinson's disease cases and controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427316     DOI: 10.1016/s0304-3940(01)01935-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Dementia with Lewy bodies: no association of polymorphisms in the human synphilin gene.

Authors:  J Busby; K K O'Brien; A M Gibson; I G McKeith; R H Perry; J A Hardy; A B Singleton; C M Morris
Journal:  Neurogenetics       Date:  2004-12       Impact factor: 2.660

2.  Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.

Authors:  Nathan Pankratz; William C Nichols; Sean K Uniacke; Cheryl Halter; Alice Rudolph; Cliff Shults; P Michael Conneally; Tatiana Foroud
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

3.  Genetic association study of synphilin-1 in idiopathic Parkinson's disease.

Authors:  Ronny Myhre; Helge Klungland; Matthew J Farrer; Jan O Aasly
Journal:  BMC Med Genet       Date:  2008-03-21       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.